The provided software implements the risk models published in the paper:
Martine Van Glabbeke, Jaap Verweij, Paolo G. Casali, John Simes, Axel Le Cesne, Peter Reichard, Rolf Issels, Ian R. Judson, Allan T. van Oosterom, Jean-Yves Blay. Predicting toxicities for patients with advanced gastro-intestinal stromal tumors (GIST) treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sacoma Group and the Australian Gastro-Intestinal Trials Group.

European Journal of Cancer 42 (2006) 2277-2285

It allows the user to estimate the probability of experiencing

• edema (CTC grade 2+),
• lethargy (CTC grade 2+),
• skin rash (CTC grade 2+),
• nausea (CTC grade 2+),
• diarrhea (CTC grade 2+),
• anemia(CTC grade 3+)
• neutropenia (CTC grade 3+)
• for individual GIST patients treated with imatinib mesylate,
  at doses ranging from 400 mg/day to 800 mg/day.

Estimations are based on the intended daily dose and 8 factors:

• Age
• Sex
• Performance status at treatment start
• Prior chemotherapy (N/Y)
• Largest diameter of the largest lesion
• Identified gastro-intestinal origin of the tumor (N/Y)
• Hemoglobin level at treatment start
• Neutrophil count at treatment start

Version available as Excel spread sheet
Compact version available for handheld computers

Software programmed by Martine Van Glabbeke,
EORTC Data Center.

Download the calculator